Table 5.
Cox Regression analysis to determine factors associated with LTFU, Tshepang Pharmacovigilance cohort, 2004-2012
| Characteristic | Univariate analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95 % CI | P value | aHR | 95 % CI | P value | ||
| Age at ART | ≥ 45 | Ref* | Ref* | ||||
| Initiation | ≥ 30 and < 45 | 0.77 | 0.50 - 1.19 | 0.240 | 0.71 | 0.37 - 1.37 | 0.310 |
| < 30 | 0.94 | 0.59 - 1.51 | 0.810 | 0.58 | 0.28 - 1.21 | 0.144 | |
| Partner status | Present | Ref* | Ref* | ||||
| Absent | 1.75 | 1.08 - 2.84 | 0.024 | 2.88 | 1.19 - 6.97 | 0.019 | |
| Employment | Employed | Ref* | Ref* | ||||
| Status | Self employed | 7.18 | 1.69 - 30.54 | 0.008 | 13.92 | 2.81 - 69.06 | 0.001 |
| Unemployed | 1.57 | 1.01 - 2.44 | 0.045 | 1.75 | 0.86 - 3.56 | 0.123 | |
| Adverse events | No | Ref* | Ref* | ||||
| Yes | 0.49 | 0.34 - 0.70 | <0.001 | 0.61 | 0.38 - 0.99 | 0.044 | |
| Baseline CD4 | CD4 ≤ 200 | Ref* | Ref* | ||||
| Count | CD4 > 200 | 2.47 | 1.42 - 4.31 | 0.001 | 3.81 | 1.85 - 7.85 | < 0.001 |
| First VL level | Undetectable VL | Ref* | Ref* | ||||
| after ART | Detectable VL | 1.81 | 1.21 - 2.72 | 0.004 | 1.00 | 0.58 - 1.73 | 0.998 |
| Last known CD4 | CD4 ≤ 200 | Ref* | Ref* | ||||
| Count | CD4 > 200 | 0.42 | 0.29 - 0.60 | < 0.001 | 0.88 | 0.51 - 1.53 | 0.651 |
| Last known VL | Undetectable VL | Ref* | Ref* | ||||
| Level | Detectable VL | 3.20 | 2.20 - 4.67 | < 0.001 | 3.60 | 1.98 - 6.52 | < 0.001 |
| Last known WHO | Stage 1 or 2 | Ref* | Ref* | ||||
| clinical stage | Stage 3 or4 | 3.20 | 2.24 - 4.57 | < 0.001 | 2.00 | 1.22 - 3.27 | 0.006 |
*Ref - Reference category